Recognized as a “Rising Star” and “Next Generation Partner” in antitrust litigation and cartels, Abram Ellis is a Partner in the Firm’s Washington, D.C. office. His practice comprises all aspects of competition law, from defending clients against complex class action antitrust litigation to helping clients obtain regulatory clearance from domestic and international competition authorities for significant transactions. Abram is particularly experienced in antitrust litigation involving complex financial instruments, the healthcare industry and employment issues. He has been recognized for his antitrust work in Euromoney’s Benchmark Litigation and The Legal 500, where he is described as “highly regarded in the market” and “a leader in the field,” and sources say that he is “a phenomenal advisor—both on day to day advisory matters, but also on complex litigation . . . He is a star.”
In addition to his robust antitrust practice, Abram advises clients on a range of regulatory matters. As Co-Head of the Firm’s International Trade Regulation Practice, he advises leading private equity funds, financial institutions and major corporations on regulatory and compliance matters relating to cross-border activities, including with respect to anti-money laundering (including CTA compliance), OFAC, FCPA and export matters. Abram also advises on anti-money laundering issues, including compliance with the Corporate Transparency Act and FinCEN’s Beneficial Ownership Information rule.
Read Full Biography...
Work Highlights
- Change Healthcare in its $13.8 billion acquisition by UnitedHealth Group, which was named “Merger Control Matter of the Year – Americas” at Global Competition Review’s GCR Awards 2023
- HCA Healthcare in FTC’s first lawsuit over COPA
- Major pharmaceutical manufacturer in dismissal of antitrust class action concerning alleged price-fixing conspiracy among manufacturers of generic pharmaceuticals
- Marinette Marine in an antitrust class action
- Tradeweb in dismissal of antitrust class actions involving interest rate swaps
- Corsair in dismissal of antitrust claims that it conspired to effect “no poach” agreements among Jackson Hewitt franchises
- 21st Century Oncology in claims alleging abuse of monopoly power over its employees
- ISDA in antitrust class actions and government investigations concerning credit default swaps
- Micron in dismissal of antitrust class actions involving DRAM
- Covestro in antitrust class actions involving MDI and TDI
- JPMorgan in antitrust and CEA class actions concerning the alleged manipulation of LIBOR
- HCA Healthcare in claims brought by North Carolina residents that HCA improperly abused its monopoly position in Asheville, North Carolina
- Tyson Foods in defending against claims that it participated in a decade-long conspiracy to fix wages of poultry plant workers
- HCA Healthcare in defeating class certification in a case alleging that HCA fixed the wages of nurses in San Antonio, Texas
- HCA Healthcare in defending against claims that it boycotted ambulatory surgery centers in Colorado
- A major manufactured housing REIT in a price-fixing class action
Accolades
-
Euromoney’s Benchmark Litigation, “Future Star”
-
The Legal 500 U.S., “Next Generation Partner”
-
Lawdragon, “500 Leading Litigators in America”
-
2014-2016 Super Lawyers “Rising Star” for Antitrust Litigation
Education
-
University of Michigan Law School, 2005 J.D.
cum laude
-
Johns Hopkins School of Advanced International Studies, 2002 M.A.
John C. Foster Award, SAIS Review Book Review Editor
-
Brigham Young University, 2000 B.A.
Associations
- New York State Bar Association
Admissions
-
U.S. Court of Appeals for the Second Circuit 2017
-
District of Columbia 2006
-
New York 2006
Based in the Washington, D.C. office, Abram Ellis is a Partner and Co-Head of the Firm’s International Trade Regulation Practice. His practice focuses on antitrust matters—including class action litigation, antitrust merger review and antitrust counseling—and on regulatory issues present in international and cross-border transactions.
Abram regularly represents clients in some of the most high-profile, pending private antitrust actions. He has also successfully helped clients navigate the antitrust merger review process, and regularly consults and advises clients on potential business activities and strategies, new industry developments and contracting activities. Abram is recognized as a “Future Star” by Euromoney’s Benchmark Litigation and a “Next Generation Partner” by The Legal 500, where he is described as “highly regarded in the market” and “a leader in the field,” and sources say that he is “a phenomenal advisor—both on day to day advisory matters, but also on complex litigation . . . He is a star.” He has also been recognized by Super Lawyers as a “Rising Star” for Antitrust Litigation, by Lawdragon’s “500 Leading Litigators in America” guide for his work involving antitrust and competition law, and The American Lawyer.
Abram also has substantial experience advising clients regarding U.S. laws relevant to international and cross-border transactions, including advising clients on matters involving regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Control and the U.S. Commerce Department’s Bureau of Industry and Security, the Foreign Corrupt Practices Act, and the Committee on Foreign Investment in the U.S.
He graduated from the University of Michigan Law School in 2005, cum laude, after obtaining an M.A. in International Relations from the Johns Hopkins University School of Advanced International Studies and a B.A. from Brigham Young University.